Lipton R B, Stewart W F
Department of Neurology, Epidemiology and Social Medicine, Albert Einstein College of Medicine, NY, USA.
Cephalalgia. 1997 Oct;17 Suppl 18:53-9. doi: 10.1177/0333102497017S1807.
Zolmitriptan (Zomig, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.
